Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock

Critical Care

Volumn 14, Issue 6, 2010, Pages

  Maybauer, Marc O ^a,b,c   Maybauer, Dirk M ^a,b   Fraser, John F ^c   Szabo, Csaba ^a   Westphal, Martin ^a   Kiss, Levente ^d   Horvath, Eszter M ^d   Nakano, Yoshimitsu ^a   Herndon, David N ^e   Traber, Lillian D ^a   Traber, Daniel L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACTIVATED PROTEIN C; DROTRECOGIN; MALONALDEHYDE; PROTEIN C; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BRAIN BLOOD FLOW; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; HEART OUTPUT; HEART RATE; ILEUM; LUNG BURN; LUNG INFECTION; MEAN ARTERIAL PRESSURE; MICROANGIOPATHY; MICROCIRCULATION; NONHUMAN; ORGAN PERFUSION; OXYGEN BREATHING; PANCREAS; PRIORITY JOURNAL; SEPTIC SHOCK; ACUTE LUNG INJURY; ANIMAL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHEEP;

ACUTE LUNG INJURY; ANIMALS; CARDIOVASCULAR DISEASES; CORONARY CIRCULATION; FEMALE; HUMANS; PROSPECTIVE STUDIES; PROTEIN C; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; SHEEP; SHOCK, SEPTIC;

EID: 78649319752     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9342     Document Type: Article

References (40)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Liaw PC. Endogenous protein C activation in patients with severe sepsis. Crit Care Med 2004, 32:S214-S218. 10.1097/01.CCM.0000126125.79861.D3, 15118520.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
4. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935, 16192478.
5. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843. 10.1016/S0140-6736(07)60411-5, 17350452.
6. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004, 21:222-229. 10.1097/01.shk.0000116778.27924.79, 14770034.
7. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003, 102:2093-2098. 10.1182/blood-2003-02-0416, 12750166.
8. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K, Mizutani A, Herndon DN, Traber DL. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med 2006, 34:2432-2438. 10.1097/01.CCM.0000230384.61350.FA, 16810106.
9. Asfar P, Hauser B, Radermacher P, Matejovic M. Catecholamines and vasopressin during critical illness. Crit Care Clin 2006, 22:131-149. vii-viii, 10.1016/j.ccc.2005.08.007, 16399024.
10. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004, 32:1011-1017. 10.1097/01.CCM.0000120058.88975.42, 15071394.
11. Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, van Gulik TM. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004, 32:1375-1383. 10.1097/01.CCM.0000128567.57761.E9, 15187522.
12. Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK, Herndon DN, Traber LD, Traber DL. A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med 2002, 30:2083-2090. 10.1097/00003246-200209000-00022, 12352045.
13. Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Cox RA, Huda R, Nakano YY, Enkhbaatar P, Hawkins HK, Herndon DN, Traber DL. Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock. Intensive Care Med 2007, 33:1219-1227. 10.1007/s00134-007-0658-3, 17503018.
14. Maybauer DM, Maybauer MO, Traber LD, Westphal M, Nakano YY, Enkhbaatar P, Morita N, Herndon DN, Traber DL. Effects of severe smoke inhalation injury and septic shock on global hemodynamics and microvascular blood flow in sheep. Shock 2006, 26:489-495. 10.1097/01.shk.0000230300.78515.ed, 17047520.
15. Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebretsen OC, Ytrehus K, Bjertnaes LJ. Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care 2008, 12:R104. 10.1186/cc6985, 2575593, 18702832.
16. Waerhaug K, Kirov MY, Kuzkov VV, Kuklin VN, Bjertnaes LJ. Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep. Crit Care 2008, 12:R146. 10.1186/cc7128, 2646309, 19021914.
17. Schenarts PJ, Bone HG, Traber LD, Traber DL. Effect of severe smoke inhalation injury on systemic microvascular blood flow in sheep. Shock 1996, 6:201-205.
18. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, Schmalstieg FC, Komjati K, Mabley JG, Szabo C, Salzman AL, Traber DL. Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 2003, 285:L240-L249.
19. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992, 101:1481-1483. 10.1378/chest.101.6.1481, 1600757.
20. Velik-Salchner C, Wenzel V, Maybauer DM, Maybauer MO. Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!. Intensive Care Med 2007, 33:2048-2050. 10.1007/s00134-007-0783-z, 17671778.
21. Maybauer MO, Traber DL, Maybauer DM. Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?. Crit Care 2009, 13:112. 2688104, 19226431.
22. Waerhaug K, Kuzkov VV, Kuklin VN, Mortensen R, Nordhus KC, Kirov MY, Bjertnaes LJ. Inhaled aerosolised recombinant human activated protein C ameliorates endotoxin-induced lung injury in anaesthetised sheep. Crit Care 2009, 13:R51. 10.1186/cc7777, 2689497, 19356243.
23. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 2005, 31:1573-1576. 10.1007/s00134-005-2792-0, 16175347.
24. Wang Z, Su F, Rogiers P, Vincent JL. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med 2007, 35:2594-2600. 10.1097/01.CCM.0000287590.55294.40, 17901839.
25. Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth Analg 2005, 101:488-498. 10.1213/01.ANE.0000177117.80058.4D, 16037166.
26. Maybauer DM, Maybauer MO, Szabo C, Westphal M, Traber LD, Enkhbaatar P, Murthy KG, Nakano Y, Salzman AL, Herndon DN, Traber DL. Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity. Biochem Biophys Res Commun 2008, 377:786-791. 10.1016/j.bbrc.2008.10.066, 2628331, 18951875.
27. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 2008, 173:2-13. 10.2353/ajpath.2008.080019, 2438280, 18535182.
28. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S. Modification of alpha1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002, 30:894-899. 10.1097/00003246-200204000-00030, 11940765.
29. Takakura K, Xiaohong W, Takeuchi K, Yasuda Y, Fukuda S. Deactivation of norepinephrine by peroxynitrite as a new pathogenesis in the hypotension of septic shock. Anesthesiology 2003, 98:928-934. 10.1097/00000542-200304000-00020, 12657855.
30. Macarthur H, Couri DM, Wilken GH, Westfall TC, Lechner AJ, Matuschak GM, Chen Z, Salvemini D. Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med 2003, 31:237-245. 10.1097/00003246-200301000-00037, 12545022.
31. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001, 104:1171-1175. 10.1161/hc3501.093799, 11535575.
32. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003, 102:1499-1505. 10.1182/blood-2002-12-3880, 12714492.
33. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005, 33:368-372. 10.1097/01.CCM.0000153415.04995.88, 15699841.
34. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, Decoster B, Zerimech F, Neviere R. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 2008, 29:572-576.
35. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW. Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009, 20:267-277. 10.1681/ASN.2008030294, 2637057, 19092124.
36. Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab 2009, 29:25-33. 10.1038/jcbfm.2008.117, 2895315, 18841163.
37. Fernandez JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003, 30:271-276. 10.1016/S1079-9796(03)00034-2, 12737945.
38. Lin XJ, Li YL, Mei GP, Zou F, He DD, Liu XQ, Li YJ, Zhao TB, Lin MT. Activated protein C can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents. Shock 2009, 32:524-529. 10.1097/SHK.0b013e3181a1a75d, 19295493.
39. Hauser B, Barth E, Bassi G, Simon F, Groger M, Oter S, Speit G, Ploner F, Moller P, Wachter U, Vogt JA, Matejovic M, Calzia E, Georgieff M, Radermacher P, Maybauer DM. Hemodynamic, metabolic, and organ function effects of pure oxygen ventilation during established fecal peritonitis-induced septic shock. Crit Care Med 2009, 37:2465-2469. 10.1097/CCM.0b013e3181aee8ad, 19531939.
40. Barth E, Bassi G, Maybauer DM, Simon F, Groger M, Oter S, Speit G, Nguyen CD, Hasel C, Moller P, Wachter U, Vogt JA, Matejovic M, Radermacher P, Calzia E. Effects of ventilation with 100% oxygen during early hyperdynamic porcine fecal peritonitis. Crit Care Med 2008, 36:495-503. 10.1097/01.CCM.0B013E318161FC45, 18091553.